Call-to-action: Timely and appropriate treatment for people with type 2 diabetes in Latin America

Diabetes Research and Clinical Practice

Volumn 104, Issue 3, 2014, Pages 343-352

  Escalante, Miguel ^a   Gagliardino, Juan José ^b   Guzmán, Juan Rosas ^c   Tschiedel, Balduino ^d  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b University of La Plata CONICET   (Argentina)

^c Centro de Especialidades Medicas de Celaya Latin University of Mexico in Celaya   (Mexico)

^d Institute for Children with Diabetes in Porto Alegre and the Brazilian Diabetes Society   (Brazil)

Author keywords

Cost of care; Diabetes mellitus, Type 2; Education; Latin America; Prevention

Indexed keywords

METFORMIN; SULFONYLUREA;

BLOOD GLUCOSE MONITORING; CONTINUING EDUCATION; COST EFFECTIVENESS ANALYSIS; EDUCATION PROGRAM; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH EDUCATION; HUMAN; INSULIN TREATMENT; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PATIENT EDUCATION; PATIENT SATISFACTION; QUALITY OF LIFE; REVIEW; SELF CARE; SOUTH AND CENTRAL AMERICA; TREATMENT INDICATION; WEIGHT REDUCTION;

COST OF CARE; DIABETES MELLITUS, TYPE 2; EDUCATION; LATIN AMERICA; PREVENTION;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; LATIN AMERICA; PATIENT-CENTERED CARE; TIME FACTORS;

EID: 84902546700     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.01.004     Document Type: Review

References (81)

1. Guzman J.R., Lyra R., Aguilar-Salinas C.A., Cavalcanti S., Escano F., Tambasia M., et al. Treatment of type 2 diabetes in Latin America: a consensus statement by the medical associations of 17 Latin American countries. Latin American Diabetes Association. Rev Panam Salud Publica 2010, 28(6):463-471.
2. International Diabetes Federation IDF diabetes atlas 2012, International Diabetes Federation, Brussels, Belgium, Available from: URL: 〈http://www.idf.org/diabetesatlas/5e/Update2012〉. 5th ed.
3. Whiting D.R., Guariguata L., Weil C., Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011, 94(3):311-321.
4. Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association. Circulation. 2007;115:114-26.
5. Gagliardino J.J., de la Hera M., Siri F. Evaluation of the quality of care for diabetic patients in Latin America. Rev Panam Salud Publica 2001, 10(5):309-317.
6. Lopez S.G., Tambascia M., Rosas G.J., Etchegoyen F., Ortega C.J., Artemenko S. Control of type 2 diabetes mellitus among general practitioners in private practice in nine countries of Latin America. Rev Panam Salud Publica 2007, 22(1):12-20.
7. Barcelo A., Aedo C., Rajpathak S., Robles S. The cost of diabetes in Latin America and the Caribbean. Bull World Health Organ 2003, 81(1):19-27.
8. Bahia L.R., Araujo D.V., Schaan B.D., Dib S.A., Negrato C.A., Leao M.P., et al. The costs of type 2 diabetes mellitus outpatient care in the Brazilian public health system. Value Health 2011, 14(5 Suppl 1):S137-S140.
9. Arredondo A., Zuniga A. Economic consequences of epidemiological changes in diabetes in middle-income countries: the Mexican case. Diabetes Care 2004, 27(1):104-109.
10. Gagliardino J.J., Kleinebreil L., Colagiuri S., Flack J., Caporale J.E., Siri F., et al. Comparison of clinical-metabolic monitoring and outcomes and coronary risk status in people with type 2 diabetes from Australia, France and Latin America. Diabetes Res Clin Pract 2010, 88(1):7-13.
11. Ringborg A., Cropet C., Jonsson B., Gagliardino J.J., Ramachandran A., Lindgren P. Resource use associated with type 2 diabetes in Asia, Latin America, the Middle East and Africa: results from the International Diabetes Management Practices Study (IDMPS). Int J Clin Pract 2009, 63(7):997-1007.
12. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.H., Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348(5):383-393.
13. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358(24):2560-2572.
14. Caporale J.E., Elgart J., Pfirter G., Martinez P., Vines G., Insua J.T., et al. Hospitalization costs for heart failure in people with type 2 diabetes: cost-effectiveness of its prevention measured by a simulated preventive treatment. Value Health 2011, 14(5 Suppl 1):S20-S23.
15. UKPDS Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352(9131):837-853.
16. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360(2):129-139.
17. Gerstein H.C., Miller M.E., Byington R.P., Goff D.C., Bigger J.T., Buse J.B., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358(24):2545-2559.
18. Brunton S., Gough S., Hicks D., Weng J., Moghissi E., Peyrot M., et al. A look into the future: improving diabetes care by 2015. Curr Med Res Opin 2011, 27(Suppl 3):65-72.
19. Chacra A.R., Davidson J.A., Diaz J., Escalante-Pulido M., Litwak L.E., Mestman J.H., et al. An algorithm for the treatment of type 2 diabetes in Latin America. Diabetes, Obes Metab 2005, 7(2):148-160.
20. UKPDS Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352(9131):854-865.
21. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359(15):1577-1589.
22. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 55(6):1577-1596.
23. Unwin N., Alberti K.G. Chronic non-communicable diseases. Ann Trop Med Parasitol 2006, 100(5-6):455-464.
24. Booth F.W., Gordon S.E., Carlson C.J., Hamilton M.T. Waging war on modern chronic diseases: primary prevention through exercise biology. J Appl Physiol 2000, 88(2):774-787.
25. Beaglehole R., Yach D. Globalisation and the prevention and control of non-communicable disease: the neglected chronic diseases of adults. Lancet 2003, 362(9387):903-908.
26. Lam D.W., LeRoith D. The worldwide diabetes epidemic. Curr Opin Endocrinol Diabetes Obes 2012, 19(2):93-96.
27. Arredondo A., De I.E. The cost of diabetes in Latin America: evidence from Mexico. Value Health 2011, 14(5 Suppl 1):S85-S88.
28. Olivera E.M., Duhalde E.P., Gagliardino J.J. Costs of temporary and permanent disability induced by diabetes. Diabetes Care 1991, 14(7):593-596.
29. Siegel K., Narayan K.M. The Unite for Diabetes campaign: overcoming constraints to find a global policy solution. Global Health 2008, 4:3.
30. Gagliardino J.J., Olivera E.M., Barragan H., Puppo R.A. A simple economic evaluation model for selecting diabetes health care strategies. Diabetic Med 1993, 10(4):351-354.
31. Khunti K., Damci T., Meneghini L., Pan C.Y., Yale J.F. Study of Once Daily Levemir (SOLVE): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice. Diabetes, Obes Metab 2012, 14(7):654-661.
32. Chan J.C., Gagliardino J.J., Baik S.H., Chantelot J.M., Ferreira S.R., Hancu N., et al. Multifaceted determinants for achieving glycemic control: the International Diabetes Management Practice Study (IDMPS). Diabetes Care 2009, 32(2):227-233.
33. Gagliardino J.J., Etchegoyen G. A model educational program for people with type 2 diabetes: a cooperative Latin American implementation study (PEDNID-LA). Diabetes Care 2001, 24(6):1001-1007.
34. Gagliardino J.J., Aschner P., Baik S.H., Chan J., Chantelot J.M., Ilkova H., et al. Patients' education, and its impact on care outcomes, resource consumption and working conditions: data from the International Diabetes Management Practices Study (IDMPS). Diabetes Metab 2012, 38(2):128-134.
35. Gagliardino J.J., Olivera E., Etchegoyen G.S., Guidi M.L., Caporale J.E., Martella A., et al. PROPAT: a study to improve the quality and reduce the cost of diabetes care. Diabetes Res Clin Pract 2006, 72(3):284-291.
36. Rodbard H.W., Jellinger P.S., Davidson J.A., Einhorn D., Garber A.J., Grunberger G., et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009, 15(6):540-559.
37. Garber A.J. Incretin therapy-present and future. Rev Diabetic Stud 2011, 8(3):307-322.
38. Gill G.V., Yudkin J.S., Keen H., Beran D. The insulin dilemma in resource-limited countries a way forward?. Diabetologia 2011, 54(1):19-24.
39. Garber A.J. Incretin effects on beta-cell function, replication, and mass: the human perspective. Diabetes Care 2011, 34(Suppl 2):S258-S263.
40. Nicolucci A., Rossi M.C. Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes. Acta Biomed 2008, 79(3):184-191.
41. Ranjit U.I., Anjana R.M., Mohan V. Importance of controlling diabetes early-the concept of metabolic memory, legacy effect and the case for early insulinisation. J Assoc Physicians India 2011, 59(Suppl):8-12.
42. Kendall D.M., Cuddihy R.M., Bergenstal R.M. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Eur J Intern Med 2009, 20(Suppl 2):S329-S339.
43. Pearson J., Powers M.A. Systematically initiating insulin: the staged diabetes management approach. Diabetes Educ 2006, 32(1 Suppl):19S-28S.
44. Wright A., Burden A.C., Paisey R.B., Cull C.A., Holman R.R. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002, 25(2):330-336.
45. Marre M. Before oral agents fail: the case for starting insulin early. Int J Obes Relat Metab Disord 2002, 26(Suppl 3):S25-S30.
46. Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995, 28(2):103-117.
47. Bretzel R.G. Intensive insulin regimens: evidence for benefit. Int J Obes Relat Metab Disord 2004, 28(Suppl 2):S8-S13.
48. Solli O., Stavem K., Kristiansen I.S. Health-related quality of life in diabetes: the associations of complications with EQ-5D scores. Health Qual Life Outcomes 2010, 8:18.
49. Zilov A.V., Wenying Y., Gonzalez-Galvez G., Home P., Jianwen C., Hasan M. Prevalence of complications of diabetes in people with type 2 diabetes: data from Asia, Europe and Latin America from the A1chieve study. Diabetes 2011, 60(Suppl 1).
50. Nichols G.A., Koo Y.H., Shah S.N. Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy. J Gen Intern Med 2007, 22(4):453-458.
51. Peyrot M., Rubin R.R., Lauritzen T., Skovlund S.E., Snoek F.J., Matthews D.R., et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005, 28(11):2673-2679.
52. Clark M. Psychological insulin resistance: a guide for practice nurses. J. Diabetes Nurs 2007, 11:53-56.
53. Cobble M.E. Initiating and intensifying insulin therapy for type 2 diabetes: why, when, and how. Am J Ther 2009, 16(1):56-64.
54. Swinnen S.G., Hoekstra J.B., DeVries J.H. Insulin therapy for type 2 diabetes. Diabetes Care 2009, 32(Suppl 2):S253-S259.
55. O'Connor P.J. Commentary-improving diabetes care by combating clinical inertia. Health Serv Res 2005, 40(6 Pt 1):1854-1861.
56. Polonsky W.H., Fisher L., Guzman S., Villa-Caballero L., Edelman S.V. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005, 28(10):2543-2545.
57. Polinski J.M., Smith B.F., Curtis B.H., Seeger J.D., Choudhry N.K., Connolly J.G., et al. Barriers to insulin progression among patients with type 2 diabetes: a systematic review. Diabetes Educ 2013, 39(1):53-65.
58. Benroubi M. Fear, guilt feelings and misconceptions: barriers to effective insulin treatment in type 2 diabetes. Diabetes Res Clin Pract 2011, 93(Suppl 1):S97-S99.
59. Oyer D.S., Shepherd M.D., Coulter F.C., Bhargava A., Brett J., Chu P.L., et al. A(1c) control in a primary care setting: self-titrating an insulin analog pre-mix (INITIATEplus trial). Am J Med 2009, 122(11):1043-1049.
60. Strange P. Treat-to-target insulin titration algorithms when initiating long or intermediate acting insulin in type 2 diabetes. J Diabetes Sci Technol 2007, 1(4):540-548.
61. Meneghini L., Koenen C., Weng W., Selam J.L. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study. Diabetes Obes Metab 2007, 9(6):902-913.
62. Barag S.H. Insulin therapy for management of type 2 diabetes mellitus: strategies for initiation and long-term patient adherence. J Am Osteopath Assoc 2011, 111(7 Suppl 5):S13-S19.
63. Beckles G.L., Engelgau M.M., Narayan K.M., Herman W.H., Aubert R.E., Williamson D.F. Population-based assessment of the level of care among adults with diabetes in the U.S. Diabetes Care 1998, 21(9):1432-1438.
64. McGlynn E.A., Asch S.M., Adams J., Keesey J., Hicks J., DeCristofaro A., et al. The quality of health care delivered to adults in the United States. N Engl J Med 2003, 348(26):2635-2645.
65. Torres H.C., Rozemberg B., Amaral M.A., Bodstein R.C. Perceptions of primary healthcare professionals towards their role in type 2 diabetes mellitus patient education in Brazil. BMC Public Health 2010, 10:583.
66. Assuncao M.C., Santos I.S., Costa J.S. Process assessment of health care: adequacy of the diabetes mellitus treatment in Pelotas, Southern Brazil. Cad. Saude Publica 2002, 18(1):205-211.
67. Mudaliar U., Kim W.C., Kirk K., Rouse C., Narayan K.M., Ali M. Are recommended standards for diabetes care met in Central and South America?. A systematic review. Diabetes Res Clin Pract 2013.
68. Larme A.C., Pugh J.A. Attitudes of primary care providers toward diabetes: barriers to guideline implementation. Diabetes Care 1998, 21(9):1391-1396.
69. Funnell MMARM Empowerment and self-management of diabetes. Clin Diabetes 2004, 22-127.
70. World Health Organization Adherence to long-term therapies: evidence for action 2003, World Health Organization, Available at: 〈http://www who int/chp/knowledge/publications/adherence_full_report pdf〉.
71. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346(6):393-403.
72. Blonde L., Merilainen M., Karwe V., Raskin P. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets-the TITRATE study. Diabetes Obes Metab 2009, 11(6):623-631.
73. Davies M., Storms F., Shutler S., Bianchi-Biscay M., Gomis R. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005, 28(6):1282-1288.
74. Ligthelm R.J. Self-titration of biphasic insulin aspart 30/70 improves glycaemic control and allows easy intensification in a Dutch clinical practice. Prim Care Diabetes 2009, 3(2):97-102.
75. Renders C.M., Valk G.D., Griffin S.J., Wagner E.H., Eijk Van J.T., Assendelft W.J. Interventions to improve the management of diabetes in primary care, outpatient, and community settings: a systematic review. Diabetes Care 2001, 24(10):1821-1833.
76. Gagliardino J.J., Arrechea V., Assad D., Gagliardino G.G., Gonzalez L., Lucero S., et al. Non-inferiority of peer education of people with type 2 diabetes in a structured environment. Diabetes Metab Res Rev 2013, 29(2):152-160.
77. Rubin R.R. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med 2005, 118(Suppl 5A):27S-34S.
78. Meetoo D.D., McAllister G., West A. Assessing glycaemic control: self-monitoring of blood glucose. Br J Nurs 2011, 20(15):919-925.
79. David L., Tetrick M.D., Christopher G., Parkin M.S. Integrating chronic care into family practice: blending the paradigms. Clin Diabetes 2013, 31:10-13.
80. van dW.I., de Leeuw J.R., Gorter K.J., Rutten G.E. Effectiveness of peer-led self-management coaching for patients recently diagnosed with Type 2 diabetes mellitus in primary care: a randomized controlled trial. Diabetic Med 2012, 29(10):e390-e397.
81. Philis-Tsimikas A., Fortmann A., Lleva-Ocana L., Walker C., Gallo L.C. Peer-led diabetes education programs in high-risk Mexican Americans improve glycemic control compared with standard approaches: a Project Dulce promotora randomized trial. Diabetes Care 2011, 34(9):1926-1931.